Glaucoma
Glaucoma is the leading cause of irreversible blindness, affecting about 3 million Americans and 80 million people worldwide. It is mainly caused by high pressure inside the eye.
Our Technology
Our disease modifying gene therapy targets a single administration for long-term, potentially life-long, lowering of intraocular pressure (IOP) in most glaucoma patients with an innovative first-in-class mechanism of action.
Our Team
Scientific leaders and industry innovators, with deep-experience in glaucoma and ophthalmology gene therapies, seeking to change the treatment paradigm for patients getting blind from glaucoma around the world.
Glaucoma
Glaucoma is the leading cause of irreversible
blindness, affecting about 3 million Americans and 80 million people worldwide. It is mainly caused by high pressure inside the eye.
Our Technology
Our disease modifying gene therapy targets a
single administration for long-term, potentially life-long, lowering of intraocular pressure (IOP) in most glaucoma patients with an innovative first-in-class mechanism of action.
Our Team
Scientific leaders and industry innovators, with
deep-experience in glaucoma and ophthalmology gene therapies, seeking to change the treatment paradign for patients getting blind from glaucoma around the world.
ABOUT US
DIORASIS THERAPEUTICS
Diorasis Therapeutics is a pre-clinical stage biotech company developing innovative ophthalmology products for common diseases aspiring to prevent blindness. The lead-compound is a first-in-class disease-modifying gene-agnostic gene therapy for normalizing outflow facility in the trabecular meshwork and decreasing intraocular pressure in patients with open angle glaucoma.
aBOUT gLaUCOMA
WHAT IS GLAUCOMA?
Glaucoma is a gradually progressive eye diseases that damages the optic nerve. The optic nerve transfers visual information from the eye to the brain. Damage to the optic nerve from glaucoma results in loss of vision and eventually complete irreversible blindness.
- High unmet medical need
- Glaucoma can develop early in life but typically average age at diagnosis is 65 years
- Glaucoma is the leading cause of irreversible blindness
- Glaucoma affecting about 3 million Americans and 80 million people worldwide.
- 300,000 new patients are diagnosed with glaucoma in the US every year
- 120,000 Americans are blind from glaucoma and 4% of newly diagnosed patients will go bilaterally blind from glaucoma despite many treatment options (including eyedrops, lasers and incisional surgery)
- High pressure inside the eye (intraocular pressure, IOP) increases risk of development and progression of vision loss in glaucoma
- IOP lowering is the only evidence-based intervention that improves prognosis
- IOP-lowering eye-drops require chronic administration, often of multiple drugs multiple times daily with significant side effects
- About 50% of patients have poor compliance because of difficulty instilling, forgetfulness, dosing frequency, lack of symptoms or side effects from eyedrops
- Poor compliance is the main reason that about 25% of patients will require glaucoma surgery at some point and 4% of newly diagnosed patients will eventually become blind
- No current treatment addresses the cause of increased IOP in open-angle glaucoma, the outflow resistance of the trabecular meshwork.
Our Technology
Focus on tissue Plasminogen Activator
- Gene-independent treatment applicable to all OAG patients with elevated IOP independent of genetic background
- Disease-modifying MOA therapy for OAG
- Decreased IOP after a single administration